Sight Sciences

SGHT

Market cap $181M

MENLO PARK, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced that two Medicare Administrative Contractors (MACs), Novitas Solutions, Inc. (Novitas) and First Coast Service Options, Inc. (FCSO), each established jurisdiction-wide pricing for CPT® code 0563T (evacuation of meibomian glands, using heat delivered through wearable, open-eye eyelid treatment devices and manual expression, bilateral), which describes the procedure performed with the Company's TearCare® System and related accessories (TearCare). The Medicare fee schedule amount is effective for dates of service on and after January 1, 2025, in all Novitas and FCSO jurisdictions and localities.

Sight Sciences highlights a new meta-analysis showing OMNI delivers lasting safety, efficacy and economic value in glaucoma treatment.

MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced the results as published in the European Journal of Ophthalmology of a systematic review and meta-analysis of the clinical effectiveness, safety, humanistic and economic impact of the OMNI Surgical System (OMNI).

Sight Sciences, Inc. (NASDAQ:SGHT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:50 PM EDT Company Participants Paul Badawi - Co-Founder, President, CEO & Director Alison Bauerlein - CFO, Principal Financial & Accounting Officer and Treasurer Presentation Unknown Analyst Awesome. Thank you so much.

UnitedHealthcare's Coverage Policy includes procedures enabled with OMNI Surgical System technology, the leader in implant-free MIGS, are proven and medically necessary UnitedHealthcare's Coverage Policy includes procedures enabled with OMNI Surgical System technology, the leader in implant-free MIGS, are proven and medically necessary

This report provides an evidence-based review of current treatments for managing dry eye disease (DED) and highlights support for TearCare based on strong clinical data This report provides an evidence-based review of current treatments for managing dry eye disease (DED) and highlights support for TearCare based on strong clinical data

MENLO PARK, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company) an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced that it will present at the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.

Sight Sciences, Inc. (NASDAQ:SGHT ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Alison Perry Bauerlein - CFO, Principal Financial & Accounting Officer and Treasurer Matthew W. Link - Chief Commercial Officer Paul Badawi - Co-Founder, President, CEO & Director Conference Call Participants Danielle Joy Antalffy - UBS Investment Bank, Research Division Frank James Takkinen - Lake Street Capital Markets, LLC, Research Division Joanne Karen Wuensch - Citigroup Inc. Exchange Research Kyle Edward Winborne - Piper Sandler & Co., Research Division Thomas M.

The headline numbers for Sight Sciences (SGHT) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.25 per share a year ago.